On February 26, 2026 Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, reported its second half 2025 results.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oncoinvent’s management team will give an online presentation to investors, analysts and the press at 09:30 CET today (details below).
Highlights:
Radspherin
Reported positive final data from Phase 1 Trial of Radspherin to treat ovarian cancer
Published Phase 1 trial results for Radspherin in ovarian cancer in Gynecologic Oncology
Presented final safety and efficacy results from the Phase 1/2a trial of Radspherin to treat colorectal cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies
Corporate
Completed merger with BerGenBio and successfully uplisted to Oslo Stock Exchange
Raised NOK 130 million in equity
Appointed Dr Ramzi Amri as Chief Financial Officer
Post-period highlights
January 2026: Included four additional sites in Oncoinvent’s Phase 2 trial
February 2026: Present positive 24-month follow-up data from Phase 1 ovarian cancer trial of Radspherin at 27th Congress of the European Society of Gynecological Oncology (ESGO) 2026
Oystein Soug, CEO, commented: "The second half of 2025 marked another productive period for Oncoinvent, with solid advances across our clinical programs together with important corporate and financial milestones. During the period, we progressed the Radspherin Phase 2 trial in ovarian cancer, delivered meaningful scientific updates in two cancer indications, completed significant strategic transactions, and in the process strengthened the company’s financial foundation ahead of the planned Phase 2 interim readout."
Presentation:
We invite to a live webcast today at 09.30 CET. It will be possible to submit questions during the presentation.
Date: Thursday, 26 February 2026
Time: 9:30am CET
Webcast link: View Source
A recording of the webcast will be made available on www.oncoinvent.com after the live sending.
Reporting material:
Oncoinvent 2H 2025 report
Oncoinvent 2H25 presentation
The reporting material are also available in the Investor Relations section of the Company’s website at www.oncoinvent.com.
(Press release, Oncoinvent, FEB 26, 2026, https://www.oncoinvent.com/press-release/oncoinvent-asa-second-half-2025-results/ [SID1234663008])